Description:
Reports Monitor Publish a New Market Research Report on – “Monoclonal Antibodies – Global Trends in the Competitive, Technological and R&D Landscape”.
Latest report, “Monoclonal Antibodies Market– Global Trends in the Competitive, Technological and R&D Landscape” discusses both the pipeline and market shares of monoclonal antibodies (mAbs) across a number of therapy areas. mAbs are defined as a collection of antibodies produced from a single B-cell clone. These antibodies therefore share binding specificity towards a certain antigen, and can be used as a means of targeted therapy within a number of indications across the pharmaceutical market.
mAbs have been in development in humans since the mid-1970s, and a substantial number of mAb products have entered the market. However, the majority are still in early-stage development, indicating delays and setbacks in the progression of potential products. Despite this, mAbs are the largest and fastest-growing segment of the biopharmaceutical sector, and account for almost half of the global revenue accrued from this area annually.
The pipeline is highly active, with 2,836 mAbs currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. Additionally, there are currently 85 mAb programs in Phase III development, and 22 at the Pre-registration stage, accounting for just under 4% of the total mAb pipeline.
Request a sample copy of Monoclonal Antibodies market report@ https://www.reportsmonitor.com/request-sample/?post=442400
Scope
– While many mAbs that enter the market achieve commercial success, a large proportion are stuck at early-stage development:
– What strategies can be put in place to advance the production of mAbs?
– What strategies can be used to improve both the affinity and therapeutic efficacy of mAbs?
– What are the relative advantages and disadvantages of each mAb type, and which hold the most promise?
…
Key Reasons to Purchase
– Understand the current status of the field of therapeutic mAbs, and the relative clinical and commercial success of currently marketed products, comprising Humira, Remicade, Rituxan, Avastin, Herceptin, Opdivo, Lucentis, Stelara and Soliris
– Assess the pipeline for mAbs split by therapy area, mAb type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four most active therapy areas for mAbs: oncology, infectious diseases, immunology and central nervous system disorders
Make an Enquiry of Monoclonal Antibodies market report@ https://www.reportsmonitor.com/make-enquiry/?post=442400
Table of Contents
Overview of mAbs 4
2.1 Initial mAb Development 6
2.2 Transition to Therapeutics 6
2.3 Present-Day Clinical and Research Applications 7
2.4 Commercial Progress within the mAb Market 8
3 Manufacture and Mechanism of mAbs 10
3.1 Classification of mAbs 10
3.1.1 By Type 10
3.1.2 By Target Specificity 11
3.1.3 By Mechanism of Action 13
3.2 Production of mAbs 15
3.2.1 Hybridomas 15
3.2.2 Phage Libraries/Phage Display 17
3.2.3 Transgenic Animals 18
3.3 Challenges in the mAb Market 18
3.3.1 Strategies for Improving mAb Efficacy 18
3.3.2 Biosimilars and Biobetters 21
4 Major mAb-Targeting Therapy Areas 23
4.1 Anti-Cancer 23
4.2 Anti-Inflammatory/Autoimmune 25
5 Key Marketed mAb Products 27
Continued…
Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Monoclonal Antibodies Market Research Report @ https://www.reportsmonitor.com/monoclonal-antibodies-global-trends-in-the-competitive-technological-and-rd-landscape/
In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
About us
We at Reports Monitor provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is providing a detailed analysis of the vast markets worldwide, backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.